Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition

Journal of Immunology

Volumn 162, Issue 6, 1999, Pages 3273-3279

  Zaks, Tal Z ^a   Chappell, Dale B ^b   Rosenberg, Steven A ^a   Restifo, Nicholas P ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CHROMIUM 51; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; OKT 3; TRIPEPTIDE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOLYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD95; APOPTOSIS; CASPASES; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE PROTEINASE INHIBITORS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FAS LIGAND PROTEIN; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; RECEPTORS, ANTIGEN, T-CELL; TUMOR CELLS, CULTURED;

EID: 0033559564     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.
2. Lee, D. S., D. E. White, R. Hurst, S. A. Rosenberg, and J. C. Yang. 1998. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J. Sci. Am. 4:86.
3. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
4. 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 73:1731.
5. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
6. Topalian, S. L., L. M. Muul, D. Solomon, and S. A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102:127.
7. +)-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195.
8. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205.
9. Smith, D., S. Sieg, and D. Kaplan. 1998. Technical note: aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J. Immunol. 160:4159.
10. Fiedler, P., C. E. Schaetzlein, and H. Eibel. 1998. Constitutive expression of FasL in thyrocytes. Science 279:2015a.
11. Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature 373:438.
12. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, and C. F. Ware. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441.
13. Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444.
14. Chappell, D. B., T. Z. Zaks, S. A. Rosenberg, and N. P. Restifo. 1999. Inflammation or immunosuppression: human melanoma cells do not express Fas (Apo-1/CD95) ligand, Cancer Res. 59:59.
15. Lenardo, M. J. 1991. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353:858.
16. Lenardo, M. J. 1997. The molecular regulation of lymphocyte apoptosis. Semin. Immunol. 9:1.
17. Fisher, G. H., F. J. Rosenberg, S. E. Straus, J. K. Dale, L. A. Middleton, A. Y. Lin, W. Strober, M. J. Lenardo, and J. M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935.
18. Trentin, L., R. Zambello, P. Bulian, A. Cerutti, C. Enthammer, M. Cassatella, D. Nitti, M. Lise, C. Agostini, and G. Semenzato. 1995. Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor. Br J. Cancer 71:240.
19. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher, and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonie adenocarcinomas. Proc. Natl. Acad. Sci. USA 94:6420.
20. Niehans, G. A., T. Brunner, S. P. Frizelle, J. C. Liston, C. T. Salerno, D. J. Knapp, D. R. Green, and R. A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57:1007.
21. Wong, B., J. Arron, and Y. Choi. 1997. T cell receptor signals enhance susceptibility in Fas-mediated apoptosis. J. Exp. Med. 186-1939.
22. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-indcpendent mechanisms for tumor killing. J. Immunol. 161:1220.
23. Hirata, H., A. Takahashi, S. Kobayashi, S. Yonchara, H. Sawai, T. Okazaki, K. Yamamoto, and M. Sasada. 1998. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 187:587.
24. Miller, D. K. 1997. The role of the caspase family of cysteine proteases in apoptosis. Semin. Immunol. 9:35.
25. Sarin, A., M. L. Wu, and P. A. Henkart. 1996. Different interleukin-1β converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. J. Exp. Med. 184:2445.
26. Rodriguez, I., K. Matsuura, C. Ody, S. Nagata, and P. Vassalli. 1996. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med. 184:2067.
27. Longthorne, V. L., and G. T. Williams. 1997. Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J. 16:3805.
28. Chinnaiyan, A. M., W. L. Hanna, K. Orth, H. Duan, G. G. Poirier, C. J. Froelich, and V. M. Dixit. 1996. Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. Curr: Biol. 6:897.
29. Darmon, A. J., D. W. Nicholson, and R. C. Bleackley. 1995. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377: 446.
30. Sarin, A., M. S. Williams, M. A. Alexander-Miller, J. A. Berzofsky, C. M. Zacharchuk, and P. A. Henkart. 1997. Target cell lysis by CTL granule exocytosis is independent of ICF/Ced-3 family proteases. Immunity 6:209.
31. Komada, Y., Y. W. Zhou, X. L. Zhang, T. X. Chen, S. Tanaka, E. Azuma, and M. Sakurai. 1997. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Br. J. Haematol. 96:147.